Tags

Type your tag names separated by a space and hit enter

[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Ugeskr Laeger. 2015 May 11; 177(20):956-60.UL

Abstract

We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS). There is evidence that nabiximols oromucosal spray may reduce subjective symptoms of spasticity and that dronabinol is effective against neuropathic pain in patients with MS. The existing treatment system in Denmark is in conformity with the existing data and there is not sufficient evidence to modify it.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

dan

PubMed ID

26535431

Citation

Bazinski, Henadzi, et al. "[There Is Evidence for the Use of Cannabinoids for Symptomatic Treatment of Multiple Sclerosis]." Ugeskrift for Laeger, vol. 177, no. 20, 2015, pp. 956-60.
Bazinski H, Jensen HB, Stenager E. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis]. Ugeskr Laeger. 2015;177(20):956-60.
Bazinski, H., Jensen, H. B., & Stenager, E. (2015). [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis]. Ugeskrift for Laeger, 177(20), 956-60.
Bazinski H, Jensen HB, Stenager E. [There Is Evidence for the Use of Cannabinoids for Symptomatic Treatment of Multiple Sclerosis]. Ugeskr Laeger. 2015 May 11;177(20):956-60. PubMed PMID: 26535431.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis]. AU - Bazinski,Henadzi, AU - Jensen,Henrik Boye, AU - Stenager,Egon, PY - 2015/11/5/entrez PY - 2015/11/5/pubmed PY - 2017/1/31/medline SP - 956 EP - 60 JF - Ugeskrift for laeger JO - Ugeskr Laeger VL - 177 IS - 20 N2 - We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS). There is evidence that nabiximols oromucosal spray may reduce subjective symptoms of spasticity and that dronabinol is effective against neuropathic pain in patients with MS. The existing treatment system in Denmark is in conformity with the existing data and there is not sufficient evidence to modify it. SN - 1603-6824 UR - https://www.unboundmedicine.com/medline/citation/26535431/[There_is_evidence_for_the_use_of_cannabinoids_for_symptomatic_treatment_of_multiple_sclerosis]_ L2 - http://www.diseaseinfosearch.org/result/4969 DB - PRIME DP - Unbound Medicine ER -